Contents

Molecular Cancer Therapeutics
Integrating Targets, Technologies, and Treatments
June 2010 • Volume 9 • Number 6

CORRECTION

ABOUT THE COVER

A recombinant human phage display-derived antibody, DX-2647, targeting IGF-II blocks the growth of human hepatocellular tumor cells *in vitro* and *in vivo*. DX-2647 blocks the binding of IGF-II to a panel of IGFBPs and the mannose-6-phosphate receptor (IGF-IIR). A comparison of the crystal complexes of IGF-II with the Fab from DX-2647 (burgundy) and IGF-II with the IGF-IIR (green) reveals a small area of overlap in the two binding domains (Fab versus IGF-IIR) contributing mechanistically to the observed neutralizing biologic activity of this antibody. For details, see article by Dransfield and colleagues on page 1809.



Molecular Cancer Therapeutics

9 (6)

Mol Cancer Ther 2010;9:1483-1927.